buprenorphine Side Effects
Also known as: Subutex, Sublocade
Analysis of 90,121 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
90,121
Death-Related
25,836
28.7% of reports
Hospitalizations
10,461
11.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 25,836 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 13,268 |
| TOXICITY TO VARIOUS AGENTS | 8,899 |
| OVERDOSE | 6,404 |
| DRUG ABUSE | 1,762 |
| DRUG DEPENDENCE | 1,610 |
| OFF LABEL USE | 917 |
| ACCIDENTAL OVERDOSE | 791 |
| ARTHRALGIA | 772 |
| ASTHENIA | 759 |
| DIZZINESS | 708 |
| PAIN | 694 |
| ABDOMINAL PAIN UPPER | 686 |
| FATIGUE | 682 |
| CONFUSIONAL STATE | 679 |
| VOMITING | 668 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 660 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 640 |
| PEMPHIGUS | 635 |
| PSORIATIC ARTHROPATHY | 631 |
| TYPE 2 DIABETES MELLITUS | 628 |
Reactions in Hospitalization Reports
Top reactions in 10,461 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| TOXICITY TO VARIOUS AGENTS | 1,763 |
| OFF LABEL USE | 1,081 |
| DRUG ABUSE | 1,069 |
| PAIN | 978 |
| CONFUSIONAL STATE | 907 |
| OVERDOSE | 861 |
| DRUG INEFFECTIVE | 857 |
| DRUG DEPENDENCE | 833 |
| NAUSEA | 825 |
| VOMITING | 824 |
| FATIGUE | 769 |
| CONDITION AGGRAVATED | 738 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 721 |
| DYSPNOEA | 700 |
| ASTHENIA | 689 |
| FALL | 674 |
| DIZZINESS | 671 |
| HEADACHE | 659 |
| ARTHRALGIA | 649 |
| MATERNAL EXPOSURE DURING PREGNANCY | 640 |
Nearby — Related Medications
What the FAERS Data Reveals About buprenorphine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 90,121 voluntary reports linked to buprenorphine and its brand equivalents (Subutex, Sublocade), spanning 2004 through 2025. Of those, 25,836 (28.7%) listed death as an outcome and 10,461 (11.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 43% male; age distribution skews toward 18-44, with 9,031 reports in that bracket. The single most reported reaction is death with 13,278 submissions, followed by drug dependence and overdose.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.